Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction.
Trends Cardiovasc Med
; 31(1): 59-66, 2021 01.
Article
en En
| MEDLINE
| ID: mdl-31889610
ABSTRACT
Cardiac amyloidosis (CA) is considered a rare disease with poor prognosis and limited therapeutic options. However, non-biopsy diagnostic modalities as well as emerging therapies are challenging this long-held belief. Radionuclide bone scintigraphy is increasingly being used in the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CA). As such, it is expected that the number of patients diagnosed with ATTR-CA will continue to rise. Emerging therapies decrease the progressive morbidity and mortality associated with ATTR-CA. The importance of early recognition of ATTR-CA is imperative as prompt initiation of these novel agents is essential to maximize their therapeutic potential. Herein, we outline the current approach to diagnosis of ATTR-CA and review the therapeutic management of the disease.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Neuropatías Amiloides Familiares
/
Insuficiencia Cardíaca
/
Cardiomiopatías
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
/
Screening_studies
Límite:
Humans
Idioma:
En
Revista:
Trends Cardiovasc Med
Asunto de la revista:
ANGIOLOGIA
/
CARDIOLOGIA
Año:
2021
Tipo del documento:
Article
País de afiliación:
Estados Unidos